Clinical trial
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have…
NCT00003659 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003659 |
|---|---|
| Title | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia |
| Official title | A Phase II Study of Fludarabine Induction With Sequential High Dose Cyclophosphamide and Rituximab as Consolidation Therapy for Previously Untreated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, rituximab, cyclophosphamide, fludarabine phosphate |
| Enrollment | 39 |
| Start date | Sep 1, 1998 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: